ReviewTreatment-resistant depression: Definitions, review of the evidence, and algorithmic approach
Introduction
Major depressive disorder (MDD) is a multidimensional common, often severe mental disorder with an age of onset below the age of 30 in most affected individuals (Kessler et al., 2012). Major depressive disorder is associated with a high rate of non-recovery and recurrence, with chronicity rates estimated at approximately 20% (van Randenborgh et al., 2012). The estimated annual costs attributable to MDD are approximately $83 billion, with indirect costs due to decreased psychosocial function (notably workforce performance) being a major contributor (Greenberg et al., 2003). For example, it is estimated that MDD is associated with an annual loss of 27.2 workdays per ill worker (Kessler et al., 2006). The significant illness burden attributable to MDD in the general population is disproportionately accounted for by individuals who have not exhibited recovery from illness.
Consensus exists that symptomatic remission increases the probability for recovery in MDD. Available evidence indicates that the majority of individuals with MDD receiving guideline-concordant and measurement-based care do not achieve and sustain a fully remitted state with index antidepressant treatment. Results from the STAR-D study indicate that remission rates decrease, and subsequent relapse rates increase, as a function of the number of failed acute therapies. For example, the overall remission rates reported in STAR-D for the medication options were 28%, 25%, 18%, and 10% at steps 1, 2, 3, and 4, respectively. Taken together, the burden of illness attributable to MDD, the high rates of non-remission with most first-line treatment strategies, and the increasing availability of mechanistically dissimilar agents (e.g., psychosocial interventions, neurostimulatory approaches and an expanding array of complementary and alternative medicines [CAM]) provide the impetus for refining therapeutic objectives in MDD, defining treatment-resistant depression (TRD) and providing evidence-based sequential treatment strategies capable of achieving symptomatic remission (Kennedy et al., 2009a, Kennedy et al., 2009b). This narrative review broadly aims to define TRD and succinctly review the evidence supporting treatment strategies in TRD.
Section snippets
Method
We conducted a review of computerized databases (PubMed, Google Scholar) from 1980 to April 2013. “Major Depressive Disorder” was cross-referenced with treatment-resistant depression, combination, augmentation, cognition, cognitive dysfunction, cognitive deficits, dementia, memory, learning, and functional outcome. The search was augmented with a manual review of relevant article reference lists. Articles selected for review were based on author consensus, adequacy of sample size, the use of
Results
Available modalities for TRD are outlined in Table 1.
Atypical antipsychotics
Three atypical antipsychotic agents are Food & Drug Administration (FDA) approved as adjunct (i.e., aripiprazole and quetiapine) or in combination (olanzapine-fluoxetine combination [OFC]) with antidepressant therapy (Spielmans et al., 2013). Results from two meta-analyses (Spielmans et al., 2013, Nelson and Papakostas, 2009) concluded that adjunctive atypical antipsychotics are significantly more effective than placebo with an approximate two-fold higher odds of achieving remission. The
Conclusion and synthesis
Major depressive disorder is a common and often severe mental disorder associated with substantial illness related burden. Most individuals receiving conventional pharmacotherapy fail to achieve and sustain remission; a critical determinant of full functional recovery. As a consequence, the majority of individuals starting antidepressant treatment will require either an adjunctive treatment strategy or a switch to a different treatment avenue, which may include initiating and combining
Role of funding source
Publication costs associated with this paper were paid to Elsevier by Bristol-Myers Squibb Canada Co. Bristol-Myers Squibb Canada Co. did not place restrictions on the form or content of this paper.
Conflict of interest
Dr. Roger McIntyre declares that he has been on advisory boards and/or received honoraria for educational activities and/or research grants from Astra Zeneca, Bristol-Myers Squibb, Janssen-Ortho, Eli Lily, Forest, Lundbeck, Pfizer, Shire, Merck, Sepracor and Otsuka.
Dr Marie-Josée Filteau declares that she has been on advisory boards, and/or received speaker's honorarium from Bristol-Myers Squibb, CANMAT Andropause Québec, Lilly, Lundbeck, Pfizer and Valeant.
Dr. Lawrence Martin declares that he
Acknowledgements
Editorial support was provided by Elsevier, Canada.
References (44)
- et al.
Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study
J. Affect. Disord.
(2012) - et al.
Neural correlates of rapid antidepressant response to ketamine in treatment-resistant unipolar depression: a preliminary positron emission tomography study
Biol. Psychiatr.
(2013) - et al.
Canadian network for mood and anxiety treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. IV. Neurostimulation therapies
J. Affect. Disord.
(2009) - et al.
Canadian network for mood and anxiety treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. Introduction
J. Affect. Disord.
(2009) - et al.
Canadian network for mood and anxiety treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy
J. Affect. Disord.
(2009) - et al.
Staging methods for treatment resistant depression. A systematic review
J. Affect. Disord.
(2012) - et al.
Treatment resistant depression: methodological overview and operational criteria
Eur. Neuropsychopharmacol.
(1999) - et al.
Contrasting chronic with episodic depression: an analysis of distorted socio-emotional information processing in chronic depression
J. Affect. Disord.
(2012) - et al.
Cognitive behavioural therapy as an adjunct to pharmacotherapy for primary care based patients with treatment resistant depression: results of the CoBalT randomised controlled trial
Lancet
(2013) - et al.
Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study
Am. J. Psychiatr.
(2010)